Tonix Pharmaceuticals Presents New Preclinical Data At Seventh International Cancer Immunotherapy Conference 2023
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented new preclinical data at the Seventh International Cancer Immunotherapy Conference 2023. The data shows that mTNX-1700 suppresses tumor growth and increases survival rates in preclinical colorectal cancer models. It also shows single agent activity and additive effects in combination with anti-PD-1. mTNX-1700 targets myeloid-derived suppressor cells (MDSCs) in a novel mechanism to treat cancer.
September 21, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' mTNX-1700 shows promising results in preclinical colorectal cancer models, which could potentially lead to a positive impact on the company's stock.
The promising preclinical results for mTNX-1700 presented by Tonix Pharmaceuticals could potentially lead to a positive impact on the company's stock. This is because successful preclinical trials often lead to increased investor confidence, which can drive up the stock price. However, it's important to note that these are preclinical results and the drug still has to go through clinical trials.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100